中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2014年
23期
102-102,103
,共2页
瘢痕子宫%中孕引产%利凡诺%米非司酮
瘢痕子宮%中孕引產%利凡諾%米非司酮
반흔자궁%중잉인산%리범낙%미비사동
scar uterine%induced abortion in midtrimester pregnancy%rivanol%mifepristone
目的:研究利凡诺联合米非司酮用于瘢痕子宫中期妊娠引产的疗效和安全性。方法回顾性分析2011年3月至2014年3月66例瘢痕子宫中期妊娠引产患者的临床资料,其中利凡诺治疗32例(对照组),利凡诺联合米非司酮治疗34例(治疗组),比较两组患者的疗效和安全性。结果治疗组宫缩发动时间、胎儿胎盘娩出时间、出血量和胎盘残留率均显著低于对照组( P <0.01);两组软产道裂伤率和引产成功率比较,差异无统计学意义( P >0.05)。结论利凡诺联合米非司酮用于瘢痕子宫中期妊娠引产的疗效确切,安全性好,值得临床推广。
目的:研究利凡諾聯閤米非司酮用于瘢痕子宮中期妊娠引產的療效和安全性。方法迴顧性分析2011年3月至2014年3月66例瘢痕子宮中期妊娠引產患者的臨床資料,其中利凡諾治療32例(對照組),利凡諾聯閤米非司酮治療34例(治療組),比較兩組患者的療效和安全性。結果治療組宮縮髮動時間、胎兒胎盤娩齣時間、齣血量和胎盤殘留率均顯著低于對照組( P <0.01);兩組軟產道裂傷率和引產成功率比較,差異無統計學意義( P >0.05)。結論利凡諾聯閤米非司酮用于瘢痕子宮中期妊娠引產的療效確切,安全性好,值得臨床推廣。
목적:연구리범낙연합미비사동용우반흔자궁중기임신인산적료효화안전성。방법회고성분석2011년3월지2014년3월66례반흔자궁중기임신인산환자적림상자료,기중리범낙치료32례(대조조),리범낙연합미비사동치료34례(치료조),비교량조환자적료효화안전성。결과치료조궁축발동시간、태인태반면출시간、출혈량화태반잔류솔균현저저우대조조( P <0.01);량조연산도렬상솔화인산성공솔비교,차이무통계학의의( P >0.05)。결론리범낙연합미비사동용우반흔자궁중기임신인산적료효학절,안전성호,치득림상추엄。
Objective To investigate the effect of rivanol combined with mifepristone for treating induced abortion in scar uterine midtrimester pregnancy. Methods The clinical data of 66 patients with induced abortion in the scar uterine midtrimester pregnancy in our hospital from march 2011 to march 2014 were retrospectively analyzed. Among them, 32 cases were treated by rivanol(control group) and 34 cases were treated by rivanol combined with mifepristone(treatment group) . Then the effects and security were compared between the two groups. Results The initial time of uterine contraction, delivery time of fetus and placenta, bleeding volume and pla-cental residual rate in the treatment group were significantly lower than those in the control group( P < 0. 01); the laceration rate of soft birth canal and the success rate of induced abortion had no statistically significant difference between the two groups( P > 0. 05 ) . Conclusion The combination of rivanol with mifepristone has definite effect and good safety for induced abortion in scar uterine mistrimester pregnancy, and deserves to be clinically promoted.